• Publications
  • Influence
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferonExpand
  • 266
  • 12
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
Substitution of amino acid (aa) 70 and/or 91 in the core region of HCV genotype 1b (HCV‐1b) is an important predictor of hepatocarcinogenesis, but its impact on the development of hepatocellularExpand
  • 48
  • 4
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
Diabetes is present in patients with chronic hepatitis C virus infection. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for typeExpand
  • 240
  • 3
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.
OBJECTIVE Interferon (IFN) therapy reduces the incidence of hepatocarcinogenesis in patients with hepatitis C viral (HCV) infection who achieve a sustained virological response (SVR). The aim of theExpand
  • 42
  • 3
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG‐IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG‐IFN, RBV,Expand
  • 96
  • 2
  • PDF
Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy
Background: Substitution of amino acids (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of poor response to interferon + ribavirin combination therapy, but theExpand
  • 29
  • 2
Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy
Objective: To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b). Methods: This study investigated pretreatmentExpand
  • 19
  • 2
HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy
Background/Aims: The recurrence rate of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) is high even in patients receiving curative therapy. In this study, we analysed the risk factorsExpand
  • 54
  • 1
New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma
Aim:  The aim of this study was to elucidate whether the histopathological characteristics of hepatocellular carcinoma (HCC) can be predicted from baseline dynamic computed tomography (CT) images.
  • 37
  • 1
A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region
Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here,Expand
  • 74
  • 1